<< Back
Phase 1 First-in-human study of AUR112, a highly selective MALT1 inhibitor, in relapsed lymphoid malignancies.
Phase 1 First-in-human study of AUR112, a highly selective MALT1 inhibitor, in relapsed lymphoid malignancies.